AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 122 min read$JNJ

Johnson & Johnson Announces New Three-Year Data From Phase 3 GALAXI 2 And 3 Studies Showing Durable Efficacy And A Consistent Safety Profile for TREMFYA

Johnson & Johnson presented three-year data from Phase 3 GALAXI 2 and 3 studies, showing durable efficacy and consistent safety for TREMFYA in Crohn's disease. Results indicate high rates of clinical and endoscopic remission for both dosing regimens. TREMFYA is approved for Crohn's disease and other inflammatory conditions.

Original reporting
marketscreener.com
Published Oct 12, 2026, 9:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$JNJ
Bullish
high confidence
Mentioned
$JNJ
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$JNJBullishHigh
01

Why it matters

The three-year data provide the most comprehensive efficacy evidence to date, likely supporting higher sales forecasts.

02

Market read

First-time disclosure of robust long-term data for a major pharma product, creating a clear trading catalyst.

03

What to watch

Potential reimbursement challenges and the need for real-world data could temper enthusiasm.

Relevance 7/10Novelty 8/10Timing: immediate release today

Background

Johnson & Johnson's TREMFYA is an IL-23 targeting monoclonal antibody approved for multiple inflammatory diseases.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Johnson & Johnson released new three-year Phase 3 data for TREMFYA in Crohn's disease, showing high remission rates and safety.

Expected impact

likely upward pressure as the market prices in the durable efficacy data

Evidence & confidence

First disclosure of robust three-year efficacy and safety data for a key product, a material catalyst for a large-cap biotech asset.

Market effects

Sector

strengthens outlook for IBD therapeutics and may lift related biotech stocks

Regional

U.S. and European markets may see modest gains in pharma sectors

Global

reinforces confidence in large-cap pharma pipelines worldwide

Counterpoint

What could challenge this read

Investors may question commercial uptake and pricing given existing competition from ustekinumab.

Key entities

  • Company
    Johnson & Johnson

    Manufacturer of TREMFYA, reporting the trial results.

  • Product
    TREMFYA

    Guselkumab therapy for Crohn's disease.

Read at source← All news

StoryJohnson & Johnson reports three‑year remission rates for TREMFYA in Crohn’s disease

Related articles

OCT 12
$JNJMed

Johnson & Johnson's Tremfya Shows Promising Long-Term Remission

Johnson & Johnson (JNJ) reported that its drug Tremfya achieved 94% clinical remission in Crohn’s disease patients over three years in phase 3 trials. JNJ has a 1.95% dividend yield, 55% payout ratio, and 4.9% 3-year dividend growth. The stock is 35.7% above its GF Value of $194.33, trading at $263.73. JNJ has a GF Score of 83, indicating strong financial health, but insiders have been net sellers.

gurufocus.com3 min
OCT 12
$JNJMed

Johnson & Johnson Announces New Phase 3 Data Showing Consistent Combined Fistula Remission Outcomes With TREMFYA Across Clinically Important Subgroups Of Adults With Crohn's Disease With Perianal Fistula

Johnson & Johnson reported Phase 3 data showing TREMFYA achieved 28% and 27% combined fistula remission in Crohn's disease patients, vs. 10% for placebo. Subgroup analyses showed consistent results across different patient types. The study was presented at the ACG 2026 meeting.

marketscreener.com2 min
OCT 12
$JNJMedAI 9/10

J&J’s Tremfya shows fistula remission in Crohn’s subgroups

Johnson & Johnson (JNJ) reported Phase 3 data showing Tremfya achieved 28% and 27% fistula remission in Crohn's patients at Week 24, versus 10% for placebo. Subgroup analyses showed higher remission rates in specific patient groups. Tremfya is approved for Crohn's disease in the U.S. The data was presented at the American College of Gastroenterology 2026 meeting.

investing.com2 min
OCT 12
$JNJMed

J&J reports three-year tremfya data for Crohn’s disease

Johnson & Johnson (JNJ) reported three-year data from its Phase 3 GALAXI 2 and 3 studies on TREMFYA for Crohn's disease. 94% and 91% of patients achieved clinical remission with 100 mg and 200 mg doses, respectively. 52% and 61% achieved endoscopic remission. 74% remained on treatment for three years. Data was presented at the American College of Gastroenterology 2026 Annual Scientific Meeting.

investing.com2 min
OCT 12
$JNJMedAI 9/10

New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups

Johnson & Johnson announced Phase 3 data showing TREMFYA (guselkumab) achieved consistent combined fistula remission rates in Crohn's disease patients with perianal fistula, including difficult-to-treat subgroups. Remission rates were 28% and 27% for two dosing groups vs. 10% for placebo. Results were presented at the ACG 2026 Annual Scientific Meeting.

prnewswire.com2 min